Bruker (BRKR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$58.50-1.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BRKR
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $58 BRKR trades at 32× p/e, in line with its 28× p/e peer median — but our blended $50 fair value sits below the price. It's a high-confidence read. Analysts target $45–$70. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $51.50 | — | — | Analyst | high |
| graham number | 12M | $25.54 | — | — | TTM | high |
| Peer P/FCF | 12M | $15.19 | 24.6 | 0.62 | TTM | high |
| Peer P/E | 12M | $43.38 | 18.7 | 2.32 | ntm analyst | high |
| Peer P/S | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$45.00 – $70.00 (median $55.00) · 4 analysts · as of 2026-08-05
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $1.24/sh owner earnings.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $67.64 |
| 2.9 |
| 22.98 |
| TTM |
| high |
| PEG | 12M | $128.97 | 70.1 | 1.84 | TTM | high |
| residual income | 12M | $17.25 | — | — | TTM | high |
| triangulated | 12M | $53.68 | 28.3 | 1.90 | Triangulated | high |
| Peer P/FCF | 3Y | $7.19 | 24.6 | 0.29 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $46.38 | 18.7 | 2.48 | Analyst | medium |
| Peer P/S | 3Y | $73.54 | 2.9 | 24.98 | guidance | medium |
| PEG | 3Y | $173.73 | 70.1 | 2.48 | Analyst | medium |
| Peer P/E | 5Y | $47.86 | 18.7 | 2.56 | Analyst | medium |
| Peer P/S | 5Y | $75.89 | 2.9 | 25.78 | guidance | medium |
| PEG | 5Y | $179.28 | 70.1 | 2.56 | Analyst | medium |